Ubiquitous Optical Healthcare Technologies (ubOHT) Programme Grant

无处不在的光学医疗保健技术 (ubOHT) 计划拨款

• 批准号: EP/X037770/1
• 负责人: Jeremy Baumberg
• 金额: $ 879.75万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FX037770%2F1
• 关键词: Ubiquitous; Optical; Healthcare; Technologies; ubOHT

Vision: to drive and promote advances in optical biosensing capable of translation to low-cost monitoring, and to build a broad UK community in low-cost sensing for healthcare.Precision medicine tailors healthcare to individual patient characteristics. We are now entering a new era of precision health, which shifts towards healthy individuals, asking how we prevent disease with appropriate interventions, prolonging healthy lifespans. New challenges include the urgent need for precise technologies to monitor individuals throughout life, and for improved methods to interpret this wealth of data. Precision health demands new physical biosensors that are low-cost but elicit rich biochemical information and can be used outside the clinic. This frees up clinician-time and focusses scarce resources. It is vital to develop methods to extract/exploit downstream patient-specific information from the sensors. Current exemplars ('BioSensors 1.0') are wearable devices (such as Fitbit, Apple watch), which record only superficial parameters (eg. temperature, acceleration, blood oxygenation), while glucose/insulin sensors provide only very specific data; the major challenge of providing comprehensive analytical information with an affordable portable device remains key for healthcare. The SARS CoV-2 lateral flow tests popularised the notion of personalised disease testing and showed it can be a reality however they lack sensitivity, reliable and consistent interpretation, and robust reporting capabilities. The leading groups assembled here have a track record of pioneering optical approaches for new paradigms in the biosensing domain, from conception through to market. Together, they propose to synergistically explore the underpinning fundamental science of 'BioSensors 2.0' and develop key demonstrators that address clinical needs while building a broader UK community of academics, SMEs, institutes, & clinicians to drive this paradigm to real demonstrators.Current portable sensors are too simple and limited in their capability. Instead, we need to translate advanced lab-based technologies into portable devices. Systems aspects need care, while miniaturisation is challenging. Sensors should achieve multiplexing, use machine learning algorithms to interpret outcomes, auto-calibrate to ensure long term operation, survive changing conditions, and attain small-enough limits of detection required for various biofluids. This is a time-critical juncture, as other countries will start to develop in this space, though nothing explicitly exists yet- the NHS as the main UK provider may be a great driver.We also focus on community building, with targeted activities to ensure the UK is placed to capitalise on sensor developments. Through building a Big Idea 'Making Senses' for the Research Councils across the wider Sensors ecosystem, our team identified with EPSRC the lack of UK leadership and joined-up academia-industry-govt networks. Engaging with a wide range of stakeholders from SMEs to large entities (NPL, CPI, LGC, Turing..) and multinationals (P&G, AstraZeneca,..), we find strong appetite and market pull for new types of biosensors with application domains beyond the hospital, as well as industrial settings. New ways to leverage light-matter interactions (in which the is UK internationally strong) for realistic biodiagnostics demands a broad interdisciplinary research focus. This confluence aims to develop entirely new industries of the future, and to energise the UK interdisciplinary science base, which is vital over the next 50 years as we realise the new paradigm of BioSensors 2.0.

愿景：推动和促进能够转化为低成本监测的光学生物传感技术的进步，并建立一个广泛的英国医疗保健低成本传感社区。精准医疗根据个体患者的特点定制医疗保健。我们现在正在进入一个精准健康的新时代，这个时代转向健康的个人，询问我们如何通过适当的干预措施预防疾病，延长健康的寿命。新的挑战包括迫切需要精确的技术来监测个人的一生，并改进解释这些丰富数据的方法。精准健康需要新的物理生物传感器，这些传感器成本低，但能获得丰富的生化信息，并可在诊所外使用。这节省了临床医生的时间，并集中了稀缺的资源。开发从传感器提取/利用下游患者特定信息的方法至关重要。目前的范例（“BioSensors 1.0”）是可穿戴设备（如Fitbit，Apple Watch），它们只记录表面参数（例如：虽然血糖/胰岛素传感器只能提供非常具体的数据，但通过经济实惠的便携式设备提供全面的分析信息仍然是医疗保健的关键，这是一项重大挑战。SARS CoV-2侧流测试普及了个性化疾病测试的概念，并表明它可以成为现实，但它们缺乏灵敏度，可靠和一致的解释以及强大的报告能力。聚集在这里的领导小组在生物传感领域从概念到市场的新范式中开拓光学方法方面有着良好的记录。他们共同提议协同探索“生物传感器2.0”的基础科学，并开发满足临床需求的关键演示器，同时建立更广泛的英国学术界，中小企业，研究所和临床医生社区，以推动这一范例成为真实的演示器。目前的便携式传感器过于简单，功能有限。相反，我们需要将先进的实验室技术转化为便携式设备。系统方面需要注意，而自动化是具有挑战性的。传感器应该实现多路复用，使用机器学习算法来解释结果，自动校准以确保长期运行，适应不断变化的条件，并达到各种生物流体所需的足够小的检测限。这是一个时间紧迫的时刻，因为其他国家将开始在这一领域发展，尽管目前还没有任何明确的进展--作为英国主要提供商的NHS可能是一个巨大的推动力。我们还专注于社区建设，并开展有针对性的活动，以确保英国能够利用传感器的发展。通过在更广泛的传感器生态系统中为研究委员会建立一个“有意义”的大创意，我们的团队与EPSRC确定了英国领导力和联合起来的英国-行业-政府网络的缺乏。与从中小企业到大型实体（NPL，CPI，LGC，Turing..）的广泛利益相关者互动和跨国公司（宝洁、阿斯利康等），我们发现对新型生物传感器的强烈需求和市场需求，其应用领域超出了医院以及工业环境。利用光-物质相互作用（英国在国际上很强）进行现实生物诊断的新方法需要广泛的跨学科研究重点。这一融合旨在发展未来的全新产业，并为英国跨学科科学基础注入活力，这在未来50年内至关重要，因为我们实现了生物传感器2.0的新范式。